NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis Incorporated (OTCBB: ADXS) has provided a complete response to the FDAs questions regarding the proposed use in humans of Lovaxin C, a live Listeria vaccine directed against HPV induced disease, in the treatment of CIN. Lovaxin C is a bioengineered microbe that infects the immune system and delivers a proprietary protein comprised of an HPV antigen fused to a fragment of the Listeria protein LLO, to stimulate multiple simultaneous immune mechanisms.
